JP2011527691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527691A5 JP2011527691A5 JP2011517582A JP2011517582A JP2011527691A5 JP 2011527691 A5 JP2011527691 A5 JP 2011527691A5 JP 2011517582 A JP2011517582 A JP 2011517582A JP 2011517582 A JP2011517582 A JP 2011517582A JP 2011527691 A5 JP2011527691 A5 JP 2011527691A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- absent
- alkyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010061218 Inflammation Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010049565 Muscle fatigue Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7898308P | 2008-07-08 | 2008-07-08 | |
| US61/078,983 | 2008-07-08 | ||
| US10436408P | 2008-10-10 | 2008-10-10 | |
| US10436608P | 2008-10-10 | 2008-10-10 | |
| US10436308P | 2008-10-10 | 2008-10-10 | |
| US61/104,366 | 2008-10-10 | ||
| US61/104,364 | 2008-10-10 | ||
| US61/104,363 | 2008-10-10 | ||
| US14865809P | 2009-01-30 | 2009-01-30 | |
| US61/148,658 | 2009-01-30 | ||
| PCT/US2009/049982 WO2010006085A1 (en) | 2008-07-08 | 2009-07-08 | Fatty acid acetylated salicylates and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014026425A Division JP5901669B2 (ja) | 2008-07-08 | 2014-02-14 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527691A JP2011527691A (ja) | 2011-11-04 |
| JP2011527691A5 true JP2011527691A5 (enExample) | 2012-06-14 |
| JP5688015B2 JP5688015B2 (ja) | 2015-03-25 |
Family
ID=41114866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517582A Expired - Fee Related JP5688015B2 (ja) | 2008-07-08 | 2009-07-08 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
| JP2014026425A Expired - Fee Related JP5901669B2 (ja) | 2008-07-08 | 2014-02-14 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014026425A Expired - Fee Related JP5901669B2 (ja) | 2008-07-08 | 2014-02-14 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
Country Status (32)
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006117664A1 (en) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | New dha derivatives and their use as medicaments |
| CN101535238A (zh) | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
| EP2217224B1 (en) | 2007-11-09 | 2019-05-08 | Basf As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| DK2315740T3 (en) | 2008-07-08 | 2018-01-08 | Catabasis Pharmaceuticals Inc | Fatty Acid Acetylated Salicylates and Their Uses |
| US9085527B2 (en) * | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| HRP20190732T1 (hr) | 2009-05-08 | 2019-06-14 | Basf As | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti |
| USRE46608E1 (en) | 2009-09-01 | 2017-11-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| US8304551B2 (en) | 2009-09-01 | 2012-11-06 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| CN102822141A (zh) * | 2010-01-20 | 2012-12-12 | 普罗诺瓦生物医药挪威公司 | 水杨酸脂肪酸衍生物 |
| WO2011106688A1 (en) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
| WO2011109681A1 (en) * | 2010-03-05 | 2011-09-09 | Catabasis Pharmaceuticals, Inc. | Fatty acid cox inhibitor derivatives and their uses |
| WO2011141341A1 (en) | 2010-05-14 | 2011-11-17 | Iberhospitex, S.A. | Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers |
| SG10201509127YA (en) | 2010-11-05 | 2015-12-30 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| BR112013015604B1 (pt) | 2010-12-22 | 2021-11-03 | D. Western Therapeutics Institute, Inc | Derivado de isoquinolina-6-sulfonamida, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou prevenir glaucoma, hipertensão ocular ou doença cardiovascular |
| EP2685969A4 (en) * | 2011-03-18 | 2014-08-06 | Catabasis Pharmaceuticals Inc | USE OF INTRACELLULAR ENZYMES TO RELEASE BIOACTIVE PRODUCTS RELATED TO COVALENCE |
| WO2012154564A1 (en) * | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid phenolic derivatives and their uses |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| JP5977355B2 (ja) * | 2011-09-29 | 2016-08-24 | エコール ノルマル シュペリウール ドゥ リヨン | ペプチダーゼの蛍光発生基質 |
| UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
| JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CN104603096A (zh) * | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| EP2852571A4 (en) | 2012-05-23 | 2015-11-25 | Cellix Bio Private Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS |
| JP6202287B2 (ja) * | 2012-05-23 | 2017-09-27 | セリックスビオ プライヴェート リミテッド | 炎症性腸疾患の治療のための組成物及び方法 |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| EP2854787A4 (en) | 2012-05-25 | 2016-02-24 | Catabasis Pharmaceuticals Inc | METHODS OF DECREASING PROPANTEIN CONVERTASE SUBTILISINE / KEXINE TYPE 9 (PCSK9) |
| WO2014004951A1 (en) * | 2012-06-28 | 2014-01-03 | Kean University | Novel fatty acid-salicylate conjugates with enhanced therapeutic properties |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
| WO2014115098A1 (en) * | 2013-01-26 | 2014-07-31 | Mahesh Kandula | Compositions and methods for the treatment of neurological diseases and inflammation |
| KR102213143B1 (ko) | 2013-02-28 | 2021-02-08 | 바스프 에이에스 | 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법 |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP2889286B1 (en) * | 2013-12-30 | 2016-05-18 | Pax Forschung GmbH | Pharmaceutically active compound for use as anti-inflammatory agent |
| US9849077B2 (en) | 2014-03-10 | 2017-12-26 | Mary Kay Inc. | Skin lightening compositions |
| WO2016011319A1 (en) * | 2014-07-18 | 2016-01-21 | Biocogent, Llc | Compositions and methods comprising salicylates and polysalicylates |
| NZ736131A (en) | 2014-09-26 | 2019-04-26 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| JP6698643B2 (ja) | 2014-09-29 | 2020-05-27 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための組成物及び方法 |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
| CN107530306A (zh) | 2015-04-28 | 2018-01-02 | 普罗诺瓦生物医药挪威公司 | 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途 |
| WO2016178066A1 (en) * | 2015-05-01 | 2016-11-10 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
| NZ750126A (en) * | 2016-08-11 | 2022-07-01 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
| EP4293036A3 (en) * | 2016-10-05 | 2024-03-13 | Baylor College of Medicine | Structure of gii.4 norovirus protease -design of broad-spectrum protease inhibitors |
| EP3676243A4 (en) | 2017-09-01 | 2021-05-26 | Curtin University | SYNTHETIC DERIVATIVES OF OLEOYL-LYSOPHOSPHATIDYLINOSITOL (OLEOLYL-LPI) AND ASSOCIATED USES |
| EP3687577A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| EP3687519A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| MX2020004659A (es) * | 2017-11-06 | 2020-10-14 | Catabasis Pharmaceuticals Inc | Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular. |
| JP2021503474A (ja) * | 2017-11-17 | 2021-02-12 | 浙江越甲▲薬▼▲業▼有限公司 | 局所麻酔薬 |
| ES2996688T3 (en) | 2017-12-06 | 2025-02-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| WO2020191087A1 (en) | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
| CN114853627B (zh) * | 2022-04-26 | 2023-06-20 | 自然资源部第三海洋研究所 | 一种取代苯甲酸二十二碳六烯酰胺乙基酯衍生物及其制备方法与应用 |
| CN114853628B (zh) * | 2022-05-07 | 2023-10-13 | 自然资源部第三海洋研究所 | 一种二十二碳六烯酰酯衍生物及其制备方法和应用 |
| CN119504664B (zh) * | 2025-01-17 | 2025-06-24 | 广东医科大学附属医院 | 二十碳五烯酸衍生物及其制备方法和应用、防治神经系统疾病药物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036951A (en) * | 1973-03-12 | 1977-07-19 | Synergistics, Inc. | Ultra-violet filtration with certain aminosalicylic acid esters |
| ES428254A1 (es) | 1974-07-15 | 1976-08-16 | Inst Internacional Terapeutico | Procedimiento para la obtencion de 2-acetoxibenzoatos de n-(2-hidroxietil) amidas de acidos grasos. |
| US4199576A (en) | 1976-12-15 | 1980-04-22 | The Procter & Gamble Company | Analgesic and anti-inflammatory compositions for topical application |
| US4276430A (en) | 1976-12-15 | 1981-06-30 | The Procter & Gamble Company | Analgesic and anti-inflammatory compounds and compositions containing same |
| CA1113486A (en) | 1977-04-01 | 1981-12-01 | Alfred Halpern | Ultra-violet filtration with certain aminosalicylic acid esters |
| US4204517A (en) * | 1978-03-30 | 1980-05-27 | Rumsey Joseph N | Fireplace furnace |
| US4264517A (en) * | 1978-12-11 | 1981-04-28 | G.D. Searle & Co. | Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates |
| US4551279A (en) | 1984-01-09 | 1985-11-05 | G. D. Searle & Co. | Protease inhibitors |
| IT1196348B (it) * | 1984-11-29 | 1988-11-16 | Italfarmaco Spa | Composti ad attivita'antiinfiammatoria |
| JPS62223159A (ja) | 1986-03-25 | 1987-10-01 | Ono Pharmaceut Co Ltd | （ｎ−置換フエニル）不飽和脂肪酸アミド誘導体、それらの製造方法及びそれらを有効成分として含有する５−リポキシゲナ−ゼ阻害剤 |
| US4670465A (en) * | 1986-05-21 | 1987-06-02 | Syntex (U.S.A.) Inc. | Arachidonic acid analogs |
| US5760261A (en) * | 1990-02-28 | 1998-06-02 | Guttag; Alvin | Higher fatty acid derivatives of salicylic acid and salts thereof |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| ATE198880T1 (de) | 1993-08-02 | 2001-02-15 | Commw Scient Ind Res Org | Therapeutische verbindung - fettsäurekonjugate |
| GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| GB9508023D0 (en) * | 1995-04-20 | 1995-06-07 | Scotia Holdings Plc | Fatty acid derivatives |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| USRE40546E1 (en) | 1996-05-01 | 2008-10-21 | Scarista, Ltd. | 1,3-Propane diol esters and ethers and methods for their use in drug delivery |
| CN1187813A (zh) * | 1995-05-01 | 1998-07-15 | 斯科舍集团有限公司 | 作为生物活性化合物的脂肪酸酯 |
| ATE272055T1 (de) | 1995-05-01 | 2004-08-15 | Scarista Ltd | Nicotinsäureester und diese enthaltende pharmazeutischen zusammensetzungen |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| GB9622636D0 (en) | 1996-10-30 | 1997-01-08 | Scotia Holdings Plc | Presentation of bioactives |
| US5728732A (en) | 1996-11-27 | 1998-03-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters and retinoids |
| ATE301679T1 (de) | 1999-01-29 | 2005-08-15 | Amersham Biosciences Kk | Temperatursensitives polymer und verfahren zu seiner herstellung |
| GB9930026D0 (en) * | 1999-12-21 | 2000-02-09 | Univ Sheffield | Novel compounds of unsaturated fatty acids |
| US6387945B2 (en) | 2000-04-11 | 2002-05-14 | The Regents Of The University Of California | Lipoic acid analogs |
| EP1386908B1 (en) | 2001-01-19 | 2010-03-03 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. | Amine derivative with potassium channel regulatory function, its preparation and use |
| US6821529B2 (en) | 2001-09-05 | 2004-11-23 | Deanna Jean Nelson | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers |
| JP4321174B2 (ja) | 2002-10-24 | 2009-08-26 | ソニー株式会社 | 可逆性多色記録媒体、及びこれを用いた記録方法 |
| US20040254357A1 (en) * | 2002-12-19 | 2004-12-16 | Zaloga Gary P. | Fatty acid phenolic conjugates |
| EP1836160A1 (en) | 2004-12-24 | 2007-09-26 | CTG Pharma S.r.l. | Compounds for treating metabolic syndrome |
| US20070155747A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| EP2004169B1 (en) | 2006-04-12 | 2012-08-08 | Unilever PLC | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
| WO2009138437A1 (en) | 2008-05-13 | 2009-11-19 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
| DK2315740T3 (en) | 2008-07-08 | 2018-01-08 | Catabasis Pharmaceuticals Inc | Fatty Acid Acetylated Salicylates and Their Uses |
| US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
| WO2011044140A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Substituted thioacetic acid salicylate derivatives and their uses |
| WO2011044138A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Lipoic acid acylated salicylate derivatives and their uses |
| CN102822141A (zh) | 2010-01-20 | 2012-12-12 | 普罗诺瓦生物医药挪威公司 | 水杨酸脂肪酸衍生物 |
| WO2012003563A1 (pt) | 2010-07-07 | 2012-01-12 | Universidade Federal De Minas Gerais - Ufmg | Composições farmacêuticas antineoplásicas contendo compostos nitroaromáticos substituídos |
| EP2685969A4 (en) | 2011-03-18 | 2014-08-06 | Catabasis Pharmaceuticals Inc | USE OF INTRACELLULAR ENZYMES TO RELEASE BIOACTIVE PRODUCTS RELATED TO COVALENCE |
| WO2012149352A1 (en) | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
| US20130059801A1 (en) | 2011-08-31 | 2013-03-07 | Catabasis Pharmaceuticals, Inc. | Fatty acid amides, compositions and methods of use |
| JP6202287B2 (ja) | 2012-05-23 | 2017-09-27 | セリックスビオ プライヴェート リミテッド | 炎症性腸疾患の治療のための組成物及び方法 |
-
2009
- 2009-07-08 DK DK09790168.0T patent/DK2315740T3/en active
- 2009-07-08 WO PCT/US2009/049982 patent/WO2010006085A1/en not_active Ceased
- 2009-07-08 JP JP2011517582A patent/JP5688015B2/ja not_active Expired - Fee Related
- 2009-07-08 PT PT97901680T patent/PT2315740T/pt unknown
- 2009-07-08 PL PL09790168T patent/PL2315740T3/pl unknown
- 2009-07-08 EP EP14176625.3A patent/EP2813486B1/en not_active Not-in-force
- 2009-07-08 NO NO09790168A patent/NO2315740T3/no unknown
- 2009-07-08 SG SG2013052717A patent/SG192488A1/en unknown
- 2009-07-08 BR BRPI0915536A patent/BRPI0915536A2/pt not_active Application Discontinuation
- 2009-07-08 NZ NZ601932A patent/NZ601932A/en not_active IP Right Cessation
- 2009-07-08 CA CA2729186A patent/CA2729186C/en not_active Expired - Fee Related
- 2009-07-08 SI SI200931789T patent/SI2315740T1/en unknown
- 2009-07-08 LT LTEP09790168.0T patent/LT2315740T/lt unknown
- 2009-07-08 EP EP09790168.0A patent/EP2315740B1/en active Active
- 2009-07-08 ES ES09790168.0T patent/ES2656793T3/es active Active
- 2009-07-08 CN CN201410254305.5A patent/CN104000808A/zh active Pending
- 2009-07-08 MY MYPI20110034 patent/MY151987A/en unknown
- 2009-07-08 AU AU2009268610A patent/AU2009268610C1/en not_active Ceased
- 2009-07-08 NZ NZ590179A patent/NZ590179A/xx not_active IP Right Cessation
- 2009-07-08 KR KR1020117002838A patent/KR101708065B1/ko not_active Expired - Fee Related
- 2009-07-08 US US12/499,779 patent/US8173831B2/en not_active Expired - Fee Related
- 2009-07-08 SM SM20180035T patent/SMT201800035T1/it unknown
- 2009-07-08 ES ES14176625.3T patent/ES2656903T3/es active Active
- 2009-07-08 MX MX2011000273A patent/MX2011000273A/es active IP Right Grant
- 2009-07-08 HR HRP20180107TT patent/HRP20180107T1/hr unknown
- 2009-07-08 CN CN200980135113.XA patent/CN102149673B/zh not_active Expired - Fee Related
- 2009-07-08 HU HUE09790168A patent/HUE035896T2/en unknown
-
2010
- 2010-12-28 IL IL210318A patent/IL210318A/en active IP Right Grant
-
2011
- 2011-01-06 CO CO11001289A patent/CO6341615A2/es active IP Right Grant
- 2011-01-06 EC EC2011010746A patent/ECSP11010746A/es unknown
- 2011-01-06 ZA ZA2011/00179A patent/ZA201100179B/en unknown
- 2011-01-07 SV SV2011003798A patent/SV2011003798A/es unknown
- 2011-01-07 GT GT201100006A patent/GT201100006A/es unknown
- 2011-01-07 NI NI201100013A patent/NI201100013A/es unknown
-
2012
- 2012-03-22 US US13/427,654 patent/US9139516B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,644 patent/US8729293B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,639 patent/US8735378B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,650 patent/US8735379B2/en not_active Expired - Fee Related
-
2013
- 2013-06-20 PH PH12013501319A patent/PH12013501319A1/en unknown
-
2014
- 2014-02-14 JP JP2014026425A patent/JP5901669B2/ja not_active Expired - Fee Related
- 2014-04-11 US US14/251,257 patent/US9272984B2/en not_active Expired - Fee Related
- 2014-04-11 US US14/251,247 patent/US9458094B2/en not_active Expired - Fee Related
-
2016
- 2016-10-03 US US15/283,995 patent/US20170246193A1/en not_active Abandoned
-
2017
- 2017-12-12 US US15/839,346 patent/US20180325923A1/en not_active Abandoned
-
2018
- 2018-01-08 CY CY20181100018T patent/CY1119784T1/el unknown
-
2019
- 2019-03-14 US US16/353,575 patent/US20200046738A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,334 patent/US20210169905A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527691A5 (enExample) | ||
| JP2013510885A5 (enExample) | ||
| JP2014111643A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| FI2498610T4 (fi) | Selektiivisiä sfingosiini-1-fosfaattireseptorin modulaattoreita ja kiraalisen synteesin menetelmiä | |
| JP2009530399A5 (enExample) | ||
| JP2010511626A5 (enExample) | ||
| SI2315740T1 (en) | Fatty acids acetylated salicylates and their uses | |
| JP2007302689A5 (enExample) | ||
| JP2018510139A5 (enExample) | ||
| HRP20150167T4 (hr) | Spojevi kao antagonisti bradikinina-b1 | |
| JP2015505296A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2010522184A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| WO2011089529A4 (en) | Salicylate fatty acid derivatives | |
| JP2012524111A5 (enExample) | ||
| JP2010536766A5 (enExample) | ||
| JP2012526842A5 (enExample) | ||
| JP2009539828A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| JP2013517322A5 (enExample) | ||
| JP2009530398A5 (enExample) |